Rhythm Pharmaceuticals, Inc. (RYTM) Financial Statements (2024 and earlier)

Company Profile

Business Address 222 BERKELEY STREET
BOSTON, MA 02116
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments253,602294,582333,288347,795235,596240,964
Cash and cash equivalents115,684109,661127,677185,087113,20778,537
Short-term investments137,918184,921205,611162,708122,389162,427
Receivables13,8318,1176,2243,3281,707862
Inventory, net of allowances, customer advances and progress billings6,1785,4872,917   
Inventory6,1785,4872,917   
Other current assets   7,415   
Other undisclosed current assets10,2679,6524,39210,75112,02911,623
Total current assets:283,878317,838354,236361,874249,332253,449
Noncurrent Assets
Operating lease, right-of-use asset9901,0881,1821,2731,3591,442
Property, plant and equipment1,7732,0012,1972,4262,5592,722
Long-term investments and receivables15,51816,75416,65515,61615,78618,356
Long-term investments15,51816,75416,65515,61615,78618,356
Intangible assets, net (including goodwill)7,4567,6697,8838,0978,3118,527
Intangible assets, net (excluding goodwill)7,4567,6697,8838,0978,3118,527
Other undisclosed noncurrent assets328328328328328328
Total noncurrent assets:26,06527,84028,24527,74028,34331,375
TOTAL ASSETS:309,943345,678382,481389,614277,675284,824
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities44,09143,89637,69130,67441,61737,209
Accounts payable8,38313,3474,7974,9336,01212,010
Accrued liabilities35,70830,54932,89425,74135,60525,199
Deferred revenue1,2861,4281,4341,7602,3099,440
Other undisclosed current liabilities726705684664644625
Total current liabilities:46,10346,02939,80933,09844,57047,274
Noncurrent Liabilities
Long-term debt and lease obligation    1,4401,6141,781
Finance lease, liability      1,781
Liabilities, other than long-term debt80,23578,59677,070   
Deferred revenue79,34777,52075,810   
Operating lease, liability8881,0761,2601,4401,614 
Other undisclosed noncurrent liabilities1,3201,2901,34072,44134,249 
Total noncurrent liabilities:81,55579,88678,41075,32137,4771,781
Total liabilities:127,658125,915118,219108,41982,04749,055
Equity
Equity, attributable to parent182,285219,763264,262281,195195,628235,769
Common stock575656565050
Additional paid in capital991,182981,950974,356949,043823,188818,051
Accumulated other comprehensive loss(14)(6)(92)(339)(906)(629)
Accumulated deficit(808,940)(762,237)(710,058)(667,565)(626,704)(581,703)
Total equity:182,285219,763264,262281,195195,628235,769
TOTAL LIABILITIES AND EQUITY:309,943345,678382,481389,614277,675284,824

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues19,22111,46923,638  1,498
Cost of revenue
(Cost of Goods and Services Sold)
(2,236)(1,421)(1,028)(497)(378)(230)
Gross profit:16,98510,04822,610(497)(378)1,268
Operating expenses(63,589)(62,579)(49,865)(43,054)(53,784)(53,959)
Other undisclosed operating income (loss)   (14,848)4,2849,066 
Operating loss:(46,604)(52,531)(42,103)(39,267)(45,096)(52,691)
Nonoperating income (expense)(99)352(390)(1,594)95(73)
Investment income, nonoperating3,2213,4403,04192095(73)
Other nonoperating expense(17)(27)(420)(370)  
Interest and debt expense(3,303)(3,061)(3,011)(2,144)  
Loss from continuing operations before equity method investments, income taxes:(50,006)(55,240)(45,504)(43,005)(45,001)(52,764)
Other undisclosed income from continuing operations before income taxes      
Loss from continuing operations before income taxes:(50,006)(55,240)(45,504)(43,005)(45,001)(52,764)
Income tax expense      
Other undisclosed income (loss) from continuing operations   (2,190)2,144  
Loss from continuing operations:(50,006)(55,240)(47,694)(40,861)(45,001)(52,764)
Loss before gain (loss) on sale of properties:(40,861)(45,001)(52,764)
Other undisclosed net income  3,0615,201   
Net loss:(50,006)(52,179)(42,493)(40,861)(45,001)(52,764)
Other undisclosed net income attributable to parent 3,303     
Net loss available to common stockholders, diluted:(46,703)(52,179)(42,493)(40,861)(45,001)(52,764)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(50,006)(52,179)(42,493)(40,861)(45,001)(52,764)
Comprehensive loss:(50,006)(52,179)(42,493)(40,861)(45,001)(52,764)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent3,29586247567(277)(628)
Comprehensive loss, net of tax, attributable to parent:(46,711)(52,093)(42,246)(40,294)(45,278)(53,392)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: